Mergers & Acquisitions Mergers & Acquisitions

Illumina-Grail deal draws in-depth EU review

By Natalie McNelis
  • 22 Jul 2021 11:46
  • 22 Jul 2021 11:48
Illumina’s $8 billion bid to buy cancer-testing start up Grail will face an in-depth investigation, the European Commission said today.

The European Commission said it's concerned that the deal may reduce competition and innovation in the emerging market for cancer-detection tests based on sequencing technologies.

“Cancer detection tests based on next generation sequencing technologies

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News